Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024
21 5월 2024 - 5:05AM
Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage
biopharmaceutical company focused on therapeutics for rare
diseases, announced today that new analyses of data from its Phase
2 OraGrowtH210 and OraGrowtH212 clinical trials have been accepted
for presentation in two posters at the 2024 Annual Meeting of the
Endocrine Society (ENDO), to be held in Boston, MA June 1-4, 2024.
Poster Session P069 –
Monday June 3, 12:00-1:30 PM ET
- Poster MON-111 : Oral LUM-201 Restores
Pulsatile Growth Hormone Secretion and Growth Response in Moderate
Pediatric Growth Hormone Deficiency (PGHD): Key Discoveries from
Phase 2 of OraGrowtH212 Trial (Fernando Cassorla, MD, Chief of
Pediatric Endocrinology, University of Chile, et al)
Late-Breaking Poster Session P108 – Monday June 3,
12:00-1:30PM ET
- Poster MON-704: Growth Response to Oral Growth
Hormone Secretagogue LUM-201 in Children with Moderate GH
Deficiency (GHD) is dependent on the Pattern of Pulsatile GH
Secretion Stimulated by LUM-201 (Adam Stevens, MSc, PhD, Lecturer,
University of Manchester, et al)
About Lumos Pharma
Lumos Pharma, Inc. is a clinical stage
biopharmaceutical company focused on the development and
commercialization of therapeutics for rare diseases. The Company
was founded and is led by a management team with longstanding
experience in rare disease drug development. Lumos Pharma’s lead
therapeutic candidate, LUM-201, is a novel, oral growth hormone
(GH) secretagogue, seeking to transform the ~$4.7B global
GH market from injectable to oral therapy. LUM-201 is currently
being evaluated in multiple Phase 2 clinical studies in Pediatric
Growth Hormone Deficiency (PGHD) and has received Orphan Drug
Designation in both the US and EU. For more information, please
visit https://lumos-pharma.com/.
Investor & Media Contact:
Lisa MillerLumos Pharma Investor
Relations512-792-5454ir@lumos-pharma.com
Source: Lumos Pharma, Inc.
Lumos Pharma (NASDAQ:LUMO)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
Lumos Pharma (NASDAQ:LUMO)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024